Zobrazeno 1 - 10
of 383
pro vyhledávání: '"C Taxonera"'
Publikováno v:
Journal of Crohn's and Colitis. 17:i678-i680
Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib were demonstrated in the OCTAVE clinical programme.1,2 Here, we present an analysis of the numbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0ef0baac412a0f12591ac3f435e571b
https://doi.org/10.1093/ecco-jcc/jjac190.0680
https://doi.org/10.1093/ecco-jcc/jjac190.0680
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
ANALES RANM. 139:31-36
Since the first report of a disease that today we call ulcerative colitis at the end of the 18th century, the knowledge in Inflammatory Bowel Disease (IBD) has radically changed. From using tuberculostatics to treat Crohn’s disease and rectal irrig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a366587a004873f721c4f4e4613bcf04
https://doi.org/10.32440/ar.2022.139.01.doc01
https://doi.org/10.32440/ar.2022.139.01.doc01
Autor:
C Taxonera Samso, D Olivares, I Blanco, E Velasco, S Molina, G López, O N López-García, C Alba, E Rey
Publikováno v:
Journal of Crohn's and Colitis. 16:i204-i206
Background This study aimed to compare the risk of COVID-19 in patients with IBD versus the general population, and to evaluate predictors of infection acquisition, progression to severe forms, and risk of developing persistent COVID-19. We also asse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e064e0b97d17df0ec5665e4db32985f2
https://doi.org/10.1093/ecco-jcc/jjab232.242
https://doi.org/10.1093/ecco-jcc/jjab232.242
Publikováno v:
Journal of Crohn's and Colitis. 17:i652-i653
Background Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative colitis (UC) is relevant to confirm the benefit observed in clinical trials. The aim of this systematic review was to summarize reported evidence on the rea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a19ed3c2944706669eed4a25cdb2615a
https://doi.org/10.1093/ecco-jcc/jjac190.0655
https://doi.org/10.1093/ecco-jcc/jjac190.0655
Autor:
C Gargallo-Puyuelo, E Ricard, M Iborra, E Iglesias-Flores, I Vera Mendoza, R De Francisco García, M Calafat Sard, M Minguez, A Lopez- San Roman, C Taxonera, J Guardiola, J Barrio, V Laredo, L De Castro, J Gisbert, S García-Lopez, E García Planella, D Martín Arranz, X Calvet, O Merino, M Sierra, L Marquez, L Madero, P Varela, D Carpio, M Esteve, M Rivero, L Ramos, B Sicilia, R Lorente POyatos, I Marin, D Monfort, M Navarro, P VEga, J Hinojosa, C Tardillo, M F García Sepulcre, M Barreiro, E Domenech, F Gomollón
Publikováno v:
Journal of Crohn's and Colitis. 17:i539-i540
Background Female sex has been associated with a worse response to anti-TNF drugs and with discontinuation of these drugs in immune-mediated diseases. Data in Inflammatory Bowel Disease (IBD) are unclear. The aims of study are to assess possible diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c219b8fd416fa8344ddd2b5ff3a5070
https://doi.org/10.1093/ecco-jcc/jjac190.0540
https://doi.org/10.1093/ecco-jcc/jjac190.0540
Autor:
G D'Haens, C Taxonera, A Lopez-Sanroman, P Nos Mateu, S Danese, A Armuzzi, X Roblin, L Peyrin-Biroulet, R West, B Witteman, M Duijvestein, K Gecse, M Hulshoff, N Mostafavi, E Clasquin, Y Bouhnik, D Laharie
Publikováno v:
Journal of Crohn's and Colitis. 17:i19-i19
Background Crohn’s disease (CD) is a chronic, immune-mediated inflammatory condition of the intestine, for which the majority of patients still needs to undergo surgical resection. Following the most common intervention ileocolonic resection, the v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::684f21a543a83340873377a3055037e8
https://doi.org/10.1093/ecco-jcc/jjac190.0014
https://doi.org/10.1093/ecco-jcc/jjac190.0014
Autor:
David Olivares, Pilar Martínez-Montiel, B. Casis, J L Pérez Calle, Mario Calvo, Patricia Vega, Isabel Vera, A M Fuentes Coronel, R. Ferreiro, Cristina Alba, C. Taxonera Samsó, Rufo Lorente, M T Diz-Lois, M. Barreiro-de-Acosta
Publikováno v:
Journal of Crohn's and Colitis. 15:S374-S376
Background Adalimumab (ADA) dose escalation from 40 mg SC every other week (EOW) to 40 mg weekly is approved for IBD patients with loss of response. A recently registered device containing 80 mg of ADA will allow an alternative dose escalation regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b3a8ba727ba9485d0d57653fde91c07
https://doi.org/10.1093/ecco-jcc/jjab076.479
https://doi.org/10.1093/ecco-jcc/jjab076.479
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 100, Iss 11, Pp 676-681 (2008)
Introducción: el adalimumab ha demostrado, en ensayos clínicos controlados con placebo y en estudios no controlados, ser efectivo en la EC luminal y fistulosa perianal. Objetivo: evaluar la eficacia y seguridad del adalimumab como tratamiento de in
Externí odkaz:
https://doaj.org/article/69f8f2e630c547858938dd429426371c